Cambridge Healthtech Institute’s 2nd Annual

Lead Generation Strategies
( 先导化合物策略 )


Finding new drug leads as fast as possible, but also as accurately as possible, in other words compounds with high drug potential, has always been the goal in early drug discovery. Often the process is separated into two steps: ‘hit’ generation which focuses on quickly finding large numbers of compounds with questionable drug potential followed by ‘lead’ optimization to whittle down the number of hits into promising, high-drug potential leads. However, automation and other advances in biophysical approaches have married the two processes to enable smaller numbers but higher quality drug leads to be found from the start. After the successful launch of CHI’s Lead Generation Strategies conference last year, we return to convene discovery biologists and chemists to share best practices and discuss how to implement new approaches towards faster and higher quality lead generation for drug discovery.


Who should attend: Biophysical Chemists, Discovery Biologists, Computational Chemists, Medicinal Chemists, Discovery Scientists from departments in academics and industry such as lead generation, hit generation, high throughput screening, medicinal chemistry, biophysics, structural biology, biochemistry, and computational chemistry


Coverage will include, but is not limited to:                                        

  • Directed evolution or diversity-oriented ligand discovery (e.g. DNA-encoded libraries)
  • Biophysical techniques (NMR, SPR, biosensors, mass spec, thermal shift assays, isothermal calirometry)
  • Fragment-based drug discovery (FBDD) best practices
  • Integrative focused screening (artificial intelligence or machine learning applications)
  • Microscopic advances (cryoEM)
  • High-throughput imaging applications
  • Phenomics and deconvoluting targets
  • Metabolomics
  • Melding results from orthogonal approaches


* 活动内容有可能不事先告知作更动及调整。

Choose your language